Advertisement

Drugs

pp 1–6 | Cite as

Volanesorsen: First Global Approval

  • Julia PaikEmail author
  • Sean Duggan
AdisInsight Report

Abstract

Volanesorsen (Waylivra®), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL). In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based on positive results from the multinational, phase III APPROACH and COMPASS studies. Other clinical trials are ongoing to assess its utility in hypertriglyceridemia, FPL and partial lipodystrophy. This article summarizes the milestones in the development of volanesorsen leading to this first approval as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Julia Paik and Sean Duggan are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–6.CrossRefGoogle Scholar
  2. 2.
    Rocha NA, East C, Zhang J, et al. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19(12):62.CrossRefGoogle Scholar
  3. 3.
    Hanssen R, Gouni-Berthold I. Antisense oligonucleotides for the treatment of hypertriglyceridemia and hyperlipoproteinemia. Curr Pharmacol Rep. 2017;3(6):458–68.CrossRefGoogle Scholar
  4. 4.
    Akcea Therapeutics. Akcea and Ionis announce approval of WAYLIVRA® (volanesorsen) in the European Union [media release]. 7 May 2019. http://www.akceatx.com.
  5. 5.
    European Medicines Agency. Volanesorsen: EU summary of product characteristics. 2019. https://www.waylivra.eu/wp-content/uploads/2019/05/WAYLIVRA-SmPC.pdf. Accessed 4 July 2019.
  6. 6.
    Akcea Therapeutics, PTC Therapeutics. Akcea Therapeutics and PTC Therapeutics collaborate to commercialize two rare disease drugs in Latin America [media release]. 2 Aug 2018. http://www.akceatx.com.
  7. 7.
    European Medicines Agency. Volanesorsen (Waylivra®): public assessment report; 2019. https://www.ema.europa.eu/. Accessed 4 July 2019.
  8. 8.
    Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479–90.CrossRefGoogle Scholar
  9. 9.
    Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS) [abstract no. 169]. J Clin Lipidol. 2017;11(3):814–5.CrossRefGoogle Scholar
  10. 10.
    Arca M, Hsieh A, Soran H, et al. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16(7):537–46.CrossRefGoogle Scholar
  11. 11.
    Gouni-Berthold I, Alexander VJ, Digenio A, et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial [abstract no. C3-5.04]. Atheroscler Suppl. 2018;32(Suppl):25.CrossRefGoogle Scholar
  12. 12.
    Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–47.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations